Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 7684 results

  1. Maternal and child nutrition

    In development [GID-NG10191] Expected publication date: 15 January 2025

    NICE guideline
    In development

  2. Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height TSID 12070

    Awaiting development [GID-TA11641] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pridopidine for treating Huntington's disease TSID 12052

    Awaiting development [GID-TA11637] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071

    Awaiting development [GID-TA11634] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486

    Awaiting development [GID-TA11623] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [TS ID 12050]

    Awaiting development [GID-TA11628] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [TS ID 12095]

    Awaiting development [GID-TA11626] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

    In development [GID-TA11430] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Bed frames for adults in acute settings

    In development [GID-HTE10050] Expected publication date: 28 May 2025

    Health technology evaluations
    In development

  12. Lifileucel for previously treated unresectable or metastatic melanoma ID3863

    In development [GID-TA10752] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia TSID 12043

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073

    In development [GID-TA10959] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  15. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development [GID-TA11277] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development